Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Satoshi, Kawashima"'
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an appare
Externí odkaz:
https://doaj.org/article/8358aaeab0374c86b4c5f65e4528a3a5
Autor:
Naoki Sakane, Yushi Hirota, Akane Yamamoto, Junnosuke Miura, Hiroko Takaike, Sari Hoshina, Masao Toyoda, Nobumichi Saito, Kiminori Hosoda, Masaki Matsubara, Atsuhito Tone, Satoshi Kawashima, Hideaki Sawaki, Tomokazu Matsuda, Masayuki Domichi, Akiko Suganuma, Seiko Sakane, Takashi Murata
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 4, Pp 582-590 (2023)
ABSTRACT Aims/Introduction The discrepancy between HbA1c and glucose exposure may have significant clinical implications; however, the association between the hemoglobin glycation index (HGI) and clinical parameters in type 1 diabetes remains controv
Externí odkaz:
https://doaj.org/article/595c9a5d700545e5bcc092799e829267
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, On behalf of the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Abstract Background Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study
Externí odkaz:
https://doaj.org/article/1ef7c7423f7448fcaf4e64ee8157f7f8
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-16 (2020)
Abstract Background This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascul
Externí odkaz:
https://doaj.org/article/b6c9bc1a1d3f4cccabeef7301d3b3b75
Autor:
Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto, Masahiko Mori, Yasuyuki Hirashima, Kazuhiro Takehara, Kazuya Ariyoshi, Tomoyasu Kato, Shigehiro Yagishita, Akinobu Hamada, Mamiko Kawasaki, Satoshi Kawashima, Sawako Tomatsuri, Yukari Nagasaka, Hiroshi Yoshida, Ryunosuke Machida, Akihiro Hirakawa, Kenichi Nakamura, Kan Yonemori
Publikováno v:
Journal of Clinical Oncology. 41:2789-2799
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) exp
Autor:
Mitsumasa Hida, Chikamune Wada, Ryota Imai, Kodai Kitagawa, Shogo Okamatsu, Tadasuke Ohnishi, Satoshi Kawashima
Publikováno v:
Journal of Orthopaedic Surgery, Vol 28 (2020)
Background: A device that can measure posture alignment repeatedly is important for the prevention of hyperkyphosis. Objective: We devised a markerless measurement method for hyperkyphosis using digital photography and investigated the correlation wi
Externí odkaz:
https://doaj.org/article/95ff391b19c94c15bd4ad522df4e6562
Autor:
Naoki Sakane, Yushi Hirota, Akane Yamamoto, Junnosuke Miura, Hiroko Takaike, Sari Hoshina, Masao Toyoda, Nobumichi Saito, Kiminori Hosoda, Masaki Matsubara, Atsuhito Tone, Satoshi Kawashima, Hideaki Sawaki, Tomokazu Matsuda, Masayuki Domichi, Akiko Suganuma, Seiko Sakane, Takashi Murata
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 18, p2607-2615, 9p
Autor:
Ryuji Yamamoto, Satoshi Kawashima
Publikováno v:
Folia Pharmacologica Japonica. 157:62-75
Autor:
Masaru Kawai, Ryo Tanaka, Kotaro Honda, Yoshiro Imai, Kazuhisa Uchiyama, Sang-Woong Lee, Satoshi Kawashima, Kentaro Matsuo, Keitaro Tashiro
Publikováno v:
Surgical Endoscopy. 36:3285-3297
The number of overweight gastric cancer patients who are undergoing laparoscopic gastrectomy (LG) has increased in Japan. However, the relationship between obesity and surgical outcomes of LG remains unclear. Therefore, this study aimed to evaluate t
Autor:
Utopia Study Investigators, Yutaka Umayahara, Takeshi Osonoi, Hiroki Yokoyama, Tsunehiko Yamamoto, Mamiko Tsugawa, Toshihiko Shiraiwa, Naoto Katakami, Nobuichi Kuribayashi, Satoru Sumitani, Kayoko Ryomoto, Hidenori Yoshii, Keisuke Kosugi, Kazuhisa Maeda, Keiichi Torimoto, Iichiro Shimomura, Yosuke Okada, Hideki Taki, Tadashi Nakamura, Hirotaka Watada, Isao Hayashi, Tomoya Mita, Hideaki Kaneto, Yasunori Sato, Satoshi Kawashima, Kentaro Ohtoshi, Tetsuyuki Yasuda
Publikováno v:
Diabetes Therapy
Introduction Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with ty